Great Debates and Updates in Hematologic Malignancies (Mar 22 - 23, 2019)

Great Debates and Updates in Hematologic Malignancies is organized by Imedex and will be held from Mar 22 - 23, 2019 at Marina del Rey Marriott, Los Angeles, California, United States of America. This CME Conference has been Approved for a maximum of 13.0 Credits/Contact Hours.

Join us for a unique educational experience. In this 2-day, debate-style series, nationally recognized thought leaders take opposing sides on clinical and sometimes controversial topics currently disrupting the practice of hematology and oncology.

Through a comprehensive review of the latest clinical advancements in hematologic malignancies, robust audience engagement, and ample discussion, participants will leave equipped with practical implications and applications to put into practice immediately.

Use code "EVENT50" for a discount on registration!

Who Should Attend?
These live educational activities are designed to meet the educational needs of those who are involved and/or interested in the treatment of patients with multiple myeloma, lymphoma, chronic lymphocytic leukemia, and acute myeloid leukemia.
• Hematologists
• Medical Oncologists
• Physicians
• Physician Assistants
• Physicians-in-Training
• Oncology Nurses
• Pharmacists

Featured Topics:
As an event best known for its unique, debate-style format, the 2019 agenda will feature a mix of didactic lectures and debates, examining the latest and most controversial topics across the board in the field of hematologic malignancies.
• Multiple Myeloma
• Acute Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• “Not-So-Benign” Hematology
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Lymphoproliferative Diseases

Objectives :
Upon successful completion of these educational activities, participants should be able to:
• Interpret pertinent clinical trial data for standard of care and novel management strategies for hematologic malignancies and benign hematologic disorders
• Assess how integration of relevant clinical trial data into clinical practice has the potential to enhance outcomes in patients with hematologic malignancies and benign hematologic disorders
• Formulate evidence-based strategies for the management of hematologic malignancies and benign hematologic disorders that take into consideration patient risk factors, cost, disease stage, and prior therapeutic regimens

Speakers: John P. Leonard, MD, Weill Cornell Medicine, New York, NY, Joseph Mikhael, MD, City of Hope Cancer Center, Phoenix, AZ, David P. Steensma, MD, Dana-Farber Cancer Institute, Boston, MA

Time: 08:00 to 16:00